New pill tested in fight against Tough-to-Treat cancers
NCT ID NCT05109975
Summary
This is an early-stage study to find a safe dose of a new oral drug called Debio 0123 for adults with advanced solid tumors that have come back or stopped responding to standard treatments. The first part of the study will determine the highest dose patients can tolerate. The second part will further test that dose in specific cancer types to check safety and see if the drug shows any signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario de A Coruna
A Coruña, 15006, Spain
-
Institut Catala de Oncologia
Girona, 17007, Spain
-
Istituto Oncologico della Svizzera italiana - Ente Ospedaliero Cantonale
Bellinzona, 6500, Switzerland
-
Kantonsspital St. Gallen, Rorschacher Strasse 95
Sankt Gallen, 9007, Switzerland
-
START Madrid. Hospital Fundación Jimenez Diaz
Madrid, 28040, Spain
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
Universitätsspital Zürich, Dermatologische Klinik
Zurich, 8058, Switzerland
Conditions
Explore the condition pages connected to this study.